Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be 18 to \< 65 years of age, at time of randomization~* Participants must be in good health, determined from medical history and no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values~Exclusion Criteria:~* History or clinical evidence of conditions considered high risk for developing influenza-related complications~* History of confirmed influenza infection within 3 months prior to randomization.~* Febrile illness with or without respiratory symptoms~* History of malignancy within 5 years or participant is under evaluation for malignancy.~* Any condition or receipt of any medication contraindicating IM injection, as judged by the investigator.~* History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis~* Participant has a clinically significant medical condition, physical exam finding, or abnormal laboratory result.~* Prior or planned receipt of any influenza vaccine for the upcoming season.~* Received any investigational agent within 90 days or within 5 half-lives of the investigational agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- VIR-2482 (Dose 1) (Type: EXPERIMENTAL): None
- VIR-2482 (Dose 2) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).